Valuation: Denali Therapeutics Inc.

Market Cap 3.15B 2.75B 2.6B 2.36B 4.42B 302B 4.43B 31.09B 12B 154B 11.84B 11.58B 495B P/E 2026 *
-8.53x
P/E 2027 * -8.6x
Enterprise Value 2.44B 2.13B 2.01B 1.83B 3.42B 234B 3.44B 24.1B 9.3B 119B 9.18B 8.98B 384B EV / Sales 2026 *
48.3x
EV / Sales 2027 * 18.6x
Free-Float
90.04%
Yield 2026 *
-
Yield 2027 * -
1 day-2.04%
1 week-6.50%
Current month-17.00%
1 month-18.88%
3 months-15.40%
6 months-1.69%
Current year+19.44%
1 week 19.56
Extreme 19.56
21.58
1 month 19.56
Extreme 19.56
25.6
Current year 15.34
Extreme 15.34
27.3
1 year 12.58
Extreme 12.58
27.3
3 years 10.57
Extreme 10.57
33.33
5 years 10.57
Extreme 10.57
56.08
10 years 10.57
Extreme 10.57
93.94
Manager TitleAgeSince
Director of Finance/CFO 52 30/04/2022
Chief Executive Officer 50 31/07/2015
Chief Tech/Sci/R&D Officer 58 05/11/2025
Director TitleAgeSince
Director/Board Member 50 28/02/2015
Director/Board Member 73 31/03/2015
Director/Board Member 68 31/03/2015
Date Insider Type Main position Quantity % Market Cap. Importance
04/09/26 Sell

Chief Technology Officer

-1,654 0.0010%
02/09/26 Sell

Director

-11,439 0.0072%
01/09/26 Sell

Founder

-2,768 0.0017%
Change 5-day change 1-year change 3-year change Capi.($)
-2.04%-6.50%+49.62%-11.53% 3.15B
-0.31%+5.79%+48.93%+97.53% 70.88B
+0.39%+2.06%+40.91%+78.49% 62.49B
-3.21%-7.27%-17.73%+351.98% 26.21B
+0.50%+7.13%+29.43%+15.48% 26.34B
-2.64%-0.69%-0.26%-11.90% 24.13B
+0.71%+8.03%+27.22%-13.18% 20.72B
-1.26%-7.81%+169.33%+302.38% 15.36B
-0.22%+3.99%+44.28%+173.35% 14.46B
+0.73%+1.71%-7.18%+886.19% 14.25B
Average -0.74%+0.83%+38.46%+186.88% 27.8B
Weighted average by Cap. -0.49%+1.35%+36.65%+146.17%

Financials

2026 *2027 *
Net sales 50.57M 44.1M 41.64M 37.81M 70.84M 4.85B 71.14M 499M 192M 2.47B 190M 186M 7.94B 130M 113M 107M 96.84M 181M 12.43B 182M 1.28B 493M 6.32B 487M 476M 20.33B
Net income -454M -396M -374M -339M -635M -43.53B -638M -4.47B -1.73B -22.13B -1.7B -1.67B -71.21B -449M -392M -370M -336M -630M -43.13B -632M -4.43B -1.71B -21.93B -1.69B -1.65B -70.55B
Net Debt -708M -618M -583M -530M -992M -67.98B -997M -6.99B -2.7B -34.56B -2.66B -2.6B -111B -749M -653M -616M -560M -1.05B -71.84B -1.05B -7.38B -2.85B -36.52B -2.81B -2.75B -118B
Logo Denali Therapeutics Inc.
Denali Therapeutics Inc. is a biopharmaceutical company establishing a new class of biotherapeutics designed to cross the blood-brain barrier using its TransportVehicle platform. It is focused on building a portfolio of therapeutic candidates by investing in its TV franchises, i.e., Enzyme TV (ETV), Oligonucleotide TV (OTV), and Antibody TV (ATV), to advance programs for rare diseases, such as lysosomal storage diseases, and common diseases, such as Alzheimer's disease and Parkinson's disease. Its most advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (Hunter syndrome). TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for mucopolysaccharidosis IIIA (Sanfilippo syndrome type A), DNL593 (PTV:PGRN) for frontotemporal dementia-granulin, DNL628 (OTV:MAPT) for Alzheimer’s disease, and DNL952 (ETV:GAA) for Pompe disease. It is also pursuing opportunities in other disease areas including oncology.
Employees
503
Date Price Change Volume
18/09/26 US$19.72 -2.04% 2,956,193
17/09/26 US$20.13 +0.35% 1,421,472
16/09/26 US$20.06 -1.57% 1,855,649
15/09/26 US$20.38 -3.96% 1,837,314
14/09/26 US$21.22 +0.62% 1,074,015
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
19.72USD
Average target price
36.06USD
Spread / Average Target
+82.87%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DNLI Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!